nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A5—Dactinomycin—testicular cancer	0.305	0.467	CbGbCtD
Amphetamine—CYP2A6—Ifosfamide—testicular cancer	0.274	0.42	CbGbCtD
Amphetamine—CYP2D6—Vinblastine—testicular cancer	0.0458	0.07	CbGbCtD
Amphetamine—CYP2D6—Doxorubicin—testicular cancer	0.0281	0.043	CbGbCtD
Amphetamine—CARTPT—testis—testicular cancer	0.00654	0.117	CbGeAlD
Amphetamine—CARTPT—lymph node—testicular cancer	0.00474	0.0845	CbGeAlD
Amphetamine—CYP2A6—seminal vesicle—testicular cancer	0.00381	0.0679	CbGeAlD
Amphetamine—SLC22A3—embryo—testicular cancer	0.00324	0.0577	CbGeAlD
Amphetamine—SLC22A3—seminal vesicle—testicular cancer	0.00304	0.0542	CbGeAlD
Amphetamine—MAOB—embryo—testicular cancer	0.00299	0.0534	CbGeAlD
Amphetamine—MAOB—seminal vesicle—testicular cancer	0.00281	0.0501	CbGeAlD
Amphetamine—SLC18A2—testis—testicular cancer	0.00222	0.0396	CbGeAlD
Amphetamine—SLC22A5—seminal vesicle—testicular cancer	0.00221	0.0394	CbGeAlD
Amphetamine—SLC22A3—gonad—testicular cancer	0.0022	0.0391	CbGeAlD
Amphetamine—SLC6A2—gonad—testicular cancer	0.00188	0.0335	CbGeAlD
Amphetamine—SLC22A3—female gonad—testicular cancer	0.00178	0.0318	CbGeAlD
Amphetamine—SLC6A3—testis—testicular cancer	0.00168	0.03	CbGeAlD
Amphetamine—MAOB—female gonad—testicular cancer	0.00165	0.0294	CbGeAlD
Amphetamine—SLC18A2—lymph node—testicular cancer	0.00161	0.0287	CbGeAlD
Amphetamine—SLC22A3—testis—testicular cancer	0.00158	0.0282	CbGeAlD
Amphetamine—MAOB—testis—testicular cancer	0.00146	0.0261	CbGeAlD
Amphetamine—SLC6A2—testis—testicular cancer	0.00136	0.0242	CbGeAlD
Amphetamine—SLC22A5—female gonad—testicular cancer	0.0013	0.0231	CbGeAlD
Amphetamine—DRD2—testis—testicular cancer	0.00124	0.022	CbGeAlD
Amphetamine—Chest pain—Bleomycin—testicular cancer	0.00122	0.00435	CcSEcCtD
Amphetamine—Myocardial infarction—Etoposide—testicular cancer	0.00121	0.00433	CcSEcCtD
Amphetamine—Decreased appetite—Vinblastine—testicular cancer	0.00121	0.00429	CcSEcCtD
Amphetamine—Urticaria—Chlorambucil—testicular cancer	0.0012	0.00428	CcSEcCtD
Amphetamine—Body temperature increased—Chlorambucil—testicular cancer	0.0012	0.00426	CcSEcCtD
Amphetamine—Abdominal pain—Chlorambucil—testicular cancer	0.0012	0.00426	CcSEcCtD
Amphetamine—Constipation—Vinblastine—testicular cancer	0.00119	0.00423	CcSEcCtD
Amphetamine—Anaphylactic shock—Bleomycin—testicular cancer	0.00117	0.00417	CcSEcCtD
Amphetamine—Infection—Bleomycin—testicular cancer	0.00116	0.00415	CcSEcCtD
Amphetamine—SLC22A5—testis—testicular cancer	0.00115	0.0205	CbGeAlD
Amphetamine—SLC22A3—lymph node—testicular cancer	0.00115	0.0205	CbGeAlD
Amphetamine—Gastrointestinal pain—Vinblastine—testicular cancer	0.00113	0.00404	CcSEcCtD
Amphetamine—Agitation—Ifosfamide—testicular cancer	0.00113	0.00402	CcSEcCtD
Amphetamine—Angioedema—Ifosfamide—testicular cancer	0.00112	0.00399	CcSEcCtD
Amphetamine—Anorexia—Bleomycin—testicular cancer	0.00112	0.00398	CcSEcCtD
Amphetamine—Hypersensitivity—Chlorambucil—testicular cancer	0.00111	0.00397	CcSEcCtD
Amphetamine—Abdominal pain—Vinblastine—testicular cancer	0.0011	0.00391	CcSEcCtD
Amphetamine—Asthenia—Chlorambucil—testicular cancer	0.00109	0.00387	CcSEcCtD
Amphetamine—Infection—Dactinomycin—testicular cancer	0.00109	0.00387	CcSEcCtD
Amphetamine—Palpitations—Ifosfamide—testicular cancer	0.00108	0.00386	CcSEcCtD
Amphetamine—Convulsion—Ifosfamide—testicular cancer	0.00106	0.00379	CcSEcCtD
Amphetamine—MAOB—lymph node—testicular cancer	0.00106	0.0189	CbGeAlD
Amphetamine—Hypertension—Ifosfamide—testicular cancer	0.00106	0.00377	CcSEcCtD
Amphetamine—Erythema multiforme—Etoposide—testicular cancer	0.00105	0.00375	CcSEcCtD
Amphetamine—Dyspnoea—Bleomycin—testicular cancer	0.00104	0.00372	CcSEcCtD
Amphetamine—Chest pain—Ifosfamide—testicular cancer	0.00104	0.00372	CcSEcCtD
Amphetamine—Anorexia—Dactinomycin—testicular cancer	0.00104	0.00371	CcSEcCtD
Amphetamine—Diarrhoea—Chlorambucil—testicular cancer	0.00104	0.00369	CcSEcCtD
Amphetamine—TAAR1—G alpha (s) signalling events—INSL3—testicular cancer	0.00103	0.106	CbGpPWpGaD
Amphetamine—Hypersensitivity—Vinblastine—testicular cancer	0.00102	0.00364	CcSEcCtD
Amphetamine—Decreased appetite—Bleomycin—testicular cancer	0.00102	0.00363	CcSEcCtD
Amphetamine—Anaphylactic shock—Ifosfamide—testicular cancer	0.001	0.00357	CcSEcCtD
Amphetamine—Asthenia—Vinblastine—testicular cancer	0.000995	0.00354	CcSEcCtD
Amphetamine—Infection—Ifosfamide—testicular cancer	0.000994	0.00354	CcSEcCtD
Amphetamine—Tremor—Cisplatin—testicular cancer	0.000991	0.00353	CcSEcCtD
Amphetamine—SLC6A2—lymph node—testicular cancer	0.000983	0.0175	CbGeAlD
Amphetamine—Cerebrovascular accident—Methotrexate—testicular cancer	0.000983	0.0035	CcSEcCtD
Amphetamine—Hyperhidrosis—Ifosfamide—testicular cancer	0.000968	0.00345	CcSEcCtD
Amphetamine—Vomiting—Chlorambucil—testicular cancer	0.000962	0.00343	CcSEcCtD
Amphetamine—Anorexia—Ifosfamide—testicular cancer	0.000954	0.0034	CcSEcCtD
Amphetamine—Decreased appetite—Dactinomycin—testicular cancer	0.000949	0.00338	CcSEcCtD
Amphetamine—Diarrhoea—Vinblastine—testicular cancer	0.000949	0.00338	CcSEcCtD
Amphetamine—Fatigue—Dactinomycin—testicular cancer	0.000942	0.00336	CcSEcCtD
Amphetamine—Urticaria—Bleomycin—testicular cancer	0.00093	0.00331	CcSEcCtD
Amphetamine—Body temperature increased—Bleomycin—testicular cancer	0.000926	0.0033	CcSEcCtD
Amphetamine—Cerebrovascular accident—Epirubicin—testicular cancer	0.00092	0.00328	CcSEcCtD
Amphetamine—Irritability—Methotrexate—testicular cancer	0.000919	0.00328	CcSEcCtD
Amphetamine—Dizziness—Vinblastine—testicular cancer	0.000917	0.00327	CcSEcCtD
Amphetamine—Convulsion—Cisplatin—testicular cancer	0.000916	0.00326	CcSEcCtD
Amphetamine—Mood swings—Methotrexate—testicular cancer	0.000913	0.00325	CcSEcCtD
Amphetamine—Nausea—Chlorambucil—testicular cancer	0.000899	0.0032	CcSEcCtD
Amphetamine—Anxiety—Cisplatin—testicular cancer	0.000897	0.0032	CcSEcCtD
Amphetamine—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000893	0.00318	CcSEcCtD
Amphetamine—Dyspnoea—Ifosfamide—testicular cancer	0.000892	0.00318	CcSEcCtD
Amphetamine—Somnolence—Ifosfamide—testicular cancer	0.00089	0.00317	CcSEcCtD
Amphetamine—Affect lability—Epirubicin—testicular cancer	0.000887	0.00316	CcSEcCtD
Amphetamine—Vomiting—Vinblastine—testicular cancer	0.000882	0.00314	CcSEcCtD
Amphetamine—Decreased appetite—Ifosfamide—testicular cancer	0.00087	0.0031	CcSEcCtD
Amphetamine—Headache—Vinblastine—testicular cancer	0.000869	0.0031	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.000867	0.00309	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000864	0.00308	CcSEcCtD
Amphetamine—Abdominal pain—Dactinomycin—testicular cancer	0.000863	0.00308	CcSEcCtD
Amphetamine—Body temperature increased—Dactinomycin—testicular cancer	0.000863	0.00308	CcSEcCtD
Amphetamine—Fatigue—Ifosfamide—testicular cancer	0.000863	0.00307	CcSEcCtD
Amphetamine—Anaphylactic shock—Cisplatin—testicular cancer	0.000863	0.00307	CcSEcCtD
Amphetamine—Hypersensitivity—Bleomycin—testicular cancer	0.000863	0.00307	CcSEcCtD
Amphetamine—Infection—Cisplatin—testicular cancer	0.000857	0.00305	CcSEcCtD
Amphetamine—Constipation—Ifosfamide—testicular cancer	0.000856	0.00305	CcSEcCtD
Amphetamine—Mood swings—Epirubicin—testicular cancer	0.000854	0.00304	CcSEcCtD
Amphetamine—Cerebrovascular accident—Doxorubicin—testicular cancer	0.000851	0.00303	CcSEcCtD
Amphetamine—Tachycardia—Cisplatin—testicular cancer	0.000842	0.003	CcSEcCtD
Amphetamine—Asthenia—Bleomycin—testicular cancer	0.00084	0.00299	CcSEcCtD
Amphetamine—Convulsion—Etoposide—testicular cancer	0.000839	0.00299	CcSEcCtD
Amphetamine—CYP2D6—female gonad—testicular cancer	0.000837	0.0149	CbGeAlD
Amphetamine—Hypertension—Etoposide—testicular cancer	0.000836	0.00298	CcSEcCtD
Amphetamine—SLC22A5—lymph node—testicular cancer	0.000834	0.0149	CbGeAlD
Amphetamine—Hyperhidrosis—Cisplatin—testicular cancer	0.000834	0.00297	CcSEcCtD
Amphetamine—Chest pain—Etoposide—testicular cancer	0.000825	0.00294	CcSEcCtD
Amphetamine—Nausea—Vinblastine—testicular cancer	0.000824	0.00293	CcSEcCtD
Amphetamine—Abdominal pain upper—Epirubicin—testicular cancer	0.000823	0.00293	CcSEcCtD
Amphetamine—Anorexia—Cisplatin—testicular cancer	0.000822	0.00293	CcSEcCtD
Amphetamine—Affect lability—Doxorubicin—testicular cancer	0.000821	0.00293	CcSEcCtD
Amphetamine—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000818	0.00292	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000812	0.00289	CcSEcCtD
Amphetamine—Hypersensitivity—Dactinomycin—testicular cancer	0.000805	0.00287	CcSEcCtD
Amphetamine—Urticaria—Ifosfamide—testicular cancer	0.000795	0.00283	CcSEcCtD
Amphetamine—Abdominal pain—Ifosfamide—testicular cancer	0.000791	0.00282	CcSEcCtD
Amphetamine—Body temperature increased—Ifosfamide—testicular cancer	0.000791	0.00282	CcSEcCtD
Amphetamine—Anaphylactic shock—Etoposide—testicular cancer	0.00079	0.00282	CcSEcCtD
Amphetamine—Mood swings—Doxorubicin—testicular cancer	0.00079	0.00282	CcSEcCtD
Amphetamine—Infection—Etoposide—testicular cancer	0.000785	0.0028	CcSEcCtD
Amphetamine—Asthenia—Dactinomycin—testicular cancer	0.000784	0.00279	CcSEcCtD
Amphetamine—Tachycardia—Etoposide—testicular cancer	0.000771	0.00275	CcSEcCtD
Amphetamine—Dyspnoea—Cisplatin—testicular cancer	0.000769	0.00274	CcSEcCtD
Amphetamine—Erectile dysfunction—Methotrexate—testicular cancer	0.000767	0.00273	CcSEcCtD
Amphetamine—Hyperhidrosis—Etoposide—testicular cancer	0.000764	0.00272	CcSEcCtD
Amphetamine—Abdominal pain upper—Doxorubicin—testicular cancer	0.000762	0.00271	CcSEcCtD
Amphetamine—Photosensitivity reaction—Methotrexate—testicular cancer	0.00076	0.00271	CcSEcCtD
Amphetamine—Anorexia—Etoposide—testicular cancer	0.000753	0.00268	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000751	0.00268	CcSEcCtD
Amphetamine—Decreased appetite—Cisplatin—testicular cancer	0.00075	0.00267	CcSEcCtD
Amphetamine—Diarrhoea—Dactinomycin—testicular cancer	0.000747	0.00266	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000745	0.00265	CcSEcCtD
Amphetamine—Vomiting—Bleomycin—testicular cancer	0.000745	0.00265	CcSEcCtD
Amphetamine—CYP2D6—testis—testicular cancer	0.000743	0.0132	CbGeAlD
Amphetamine—Depression—Methotrexate—testicular cancer	0.00074	0.00264	CcSEcCtD
Amphetamine—Rash—Bleomycin—testicular cancer	0.000738	0.00263	CcSEcCtD
Amphetamine—Dermatitis—Bleomycin—testicular cancer	0.000738	0.00263	CcSEcCtD
Amphetamine—Hypersensitivity—Ifosfamide—testicular cancer	0.000737	0.00263	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000736	0.00262	CcSEcCtD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000735	0.0761	CbGpPWpGaD
Amphetamine—Asthenia—Ifosfamide—testicular cancer	0.000718	0.00256	CcSEcCtD
Amphetamine—Sweating—Methotrexate—testicular cancer	0.000712	0.00254	CcSEcCtD
Amphetamine—Photosensitivity reaction—Epirubicin—testicular cancer	0.000711	0.00253	CcSEcCtD
Amphetamine—Weight decreased—Epirubicin—testicular cancer	0.000705	0.00251	CcSEcCtD
Amphetamine—Dyspnoea—Etoposide—testicular cancer	0.000705	0.00251	CcSEcCtD
Amphetamine—Somnolence—Etoposide—testicular cancer	0.000703	0.0025	CcSEcCtD
Amphetamine—Nausea—Bleomycin—testicular cancer	0.000696	0.00248	CcSEcCtD
Amphetamine—Vomiting—Dactinomycin—testicular cancer	0.000694	0.00247	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000689	0.00245	CcSEcCtD
Amphetamine—Rash—Dactinomycin—testicular cancer	0.000689	0.00245	CcSEcCtD
Amphetamine—Decreased appetite—Etoposide—testicular cancer	0.000687	0.00245	CcSEcCtD
Amphetamine—Diarrhoea—Ifosfamide—testicular cancer	0.000685	0.00244	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000682	0.00243	CcSEcCtD
Amphetamine—Body temperature increased—Cisplatin—testicular cancer	0.000682	0.00243	CcSEcCtD
Amphetamine—Fatigue—Etoposide—testicular cancer	0.000682	0.00243	CcSEcCtD
Amphetamine—Constipation—Etoposide—testicular cancer	0.000676	0.00241	CcSEcCtD
Amphetamine—Urinary tract infection—Epirubicin—testicular cancer	0.000675	0.00241	CcSEcCtD
Amphetamine—Sweating—Epirubicin—testicular cancer	0.000666	0.00237	CcSEcCtD
Amphetamine—Dizziness—Ifosfamide—testicular cancer	0.000662	0.00236	CcSEcCtD
Amphetamine—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000658	0.00234	CcSEcCtD
Amphetamine—Weight decreased—Doxorubicin—testicular cancer	0.000652	0.00232	CcSEcCtD
Amphetamine—Nausea—Dactinomycin—testicular cancer	0.000649	0.00231	CcSEcCtD
Amphetamine—Gastrointestinal pain—Etoposide—testicular cancer	0.000646	0.0023	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000637	0.00227	CcSEcCtD
Amphetamine—Vomiting—Ifosfamide—testicular cancer	0.000636	0.00227	CcSEcCtD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000636	0.0658	CbGpPWpGaD
Amphetamine—Hypersensitivity—Cisplatin—testicular cancer	0.000636	0.00227	CcSEcCtD
Amphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000634	0.0656	CbGpPWpGaD
Amphetamine—Rash—Ifosfamide—testicular cancer	0.000631	0.00225	CcSEcCtD
Amphetamine—Dermatitis—Ifosfamide—testicular cancer	0.00063	0.00225	CcSEcCtD
Amphetamine—Erythema multiforme—Methotrexate—testicular cancer	0.00063	0.00225	CcSEcCtD
Amphetamine—Urticaria—Etoposide—testicular cancer	0.000628	0.00224	CcSEcCtD
Amphetamine—Abdominal pain—Etoposide—testicular cancer	0.000625	0.00223	CcSEcCtD
Amphetamine—Body temperature increased—Etoposide—testicular cancer	0.000625	0.00223	CcSEcCtD
Amphetamine—Urinary tract infection—Doxorubicin—testicular cancer	0.000625	0.00223	CcSEcCtD
Amphetamine—Asthenia—Cisplatin—testicular cancer	0.000619	0.00221	CcSEcCtD
Amphetamine—Sweating—Doxorubicin—testicular cancer	0.000616	0.0022	CcSEcCtD
Amphetamine—Nausea—Ifosfamide—testicular cancer	0.000594	0.00212	CcSEcCtD
Amphetamine—Diarrhoea—Cisplatin—testicular cancer	0.00059	0.0021	CcSEcCtD
Amphetamine—Erythema multiforme—Epirubicin—testicular cancer	0.00059	0.0021	CcSEcCtD
Amphetamine—Hypersensitivity—Etoposide—testicular cancer	0.000582	0.00208	CcSEcCtD
Amphetamine—Asthenia—Etoposide—testicular cancer	0.000567	0.00202	CcSEcCtD
Amphetamine—Vomiting—Cisplatin—testicular cancer	0.000549	0.00195	CcSEcCtD
Amphetamine—Erythema multiforme—Doxorubicin—testicular cancer	0.000546	0.00194	CcSEcCtD
Amphetamine—Rash—Cisplatin—testicular cancer	0.000544	0.00194	CcSEcCtD
Amphetamine—Dermatitis—Cisplatin—testicular cancer	0.000544	0.00194	CcSEcCtD
Amphetamine—Diarrhoea—Etoposide—testicular cancer	0.000541	0.00193	CcSEcCtD
Amphetamine—Tension—Epirubicin—testicular cancer	0.000533	0.0019	CcSEcCtD
Amphetamine—Nervousness—Epirubicin—testicular cancer	0.000527	0.00188	CcSEcCtD
Amphetamine—Dizziness—Etoposide—testicular cancer	0.000523	0.00186	CcSEcCtD
Amphetamine—Nausea—Cisplatin—testicular cancer	0.000513	0.00183	CcSEcCtD
Amphetamine—Convulsion—Methotrexate—testicular cancer	0.000503	0.00179	CcSEcCtD
Amphetamine—Vomiting—Etoposide—testicular cancer	0.000503	0.00179	CcSEcCtD
Amphetamine—Agitation—Epirubicin—testicular cancer	0.000499	0.00178	CcSEcCtD
Amphetamine—Rash—Etoposide—testicular cancer	0.000498	0.00178	CcSEcCtD
Amphetamine—Dermatitis—Etoposide—testicular cancer	0.000498	0.00177	CcSEcCtD
Amphetamine—Headache—Etoposide—testicular cancer	0.000495	0.00176	CcSEcCtD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000495	0.0512	CbGpPWpGaD
Amphetamine—Chest pain—Methotrexate—testicular cancer	0.000494	0.00176	CcSEcCtD
Amphetamine—Tension—Doxorubicin—testicular cancer	0.000493	0.00176	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00049	0.0507	CbGpPWpGaD
Amphetamine—Nervousness—Doxorubicin—testicular cancer	0.000488	0.00174	CcSEcCtD
Amphetamine—Palpitations—Epirubicin—testicular cancer	0.00048	0.00171	CcSEcCtD
Amphetamine—Anaphylactic shock—Methotrexate—testicular cancer	0.000473	0.00169	CcSEcCtD
Amphetamine—Convulsion—Epirubicin—testicular cancer	0.00047	0.00168	CcSEcCtD
Amphetamine—Infection—Methotrexate—testicular cancer	0.00047	0.00168	CcSEcCtD
Amphetamine—Nausea—Etoposide—testicular cancer	0.00047	0.00167	CcSEcCtD
Amphetamine—Hypertension—Epirubicin—testicular cancer	0.000469	0.00167	CcSEcCtD
Amphetamine—Chest pain—Epirubicin—testicular cancer	0.000462	0.00165	CcSEcCtD
Amphetamine—Agitation—Doxorubicin—testicular cancer	0.000462	0.00164	CcSEcCtD
Amphetamine—Anxiety—Epirubicin—testicular cancer	0.000461	0.00164	CcSEcCtD
Amphetamine—Hyperhidrosis—Methotrexate—testicular cancer	0.000458	0.00163	CcSEcCtD
Amphetamine—Dry mouth—Epirubicin—testicular cancer	0.000452	0.00161	CcSEcCtD
Amphetamine—Anorexia—Methotrexate—testicular cancer	0.000451	0.00161	CcSEcCtD
Amphetamine—Palpitations—Doxorubicin—testicular cancer	0.000444	0.00158	CcSEcCtD
Amphetamine—Anaphylactic shock—Epirubicin—testicular cancer	0.000443	0.00158	CcSEcCtD
Amphetamine—Infection—Epirubicin—testicular cancer	0.00044	0.00157	CcSEcCtD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000438	0.0454	CbGpPWpGaD
Amphetamine—Convulsion—Doxorubicin—testicular cancer	0.000435	0.00155	CcSEcCtD
Amphetamine—Hypertension—Doxorubicin—testicular cancer	0.000434	0.00155	CcSEcCtD
Amphetamine—Tachycardia—Epirubicin—testicular cancer	0.000432	0.00154	CcSEcCtD
Amphetamine—Hyperhidrosis—Epirubicin—testicular cancer	0.000428	0.00153	CcSEcCtD
Amphetamine—Insomnia—Methotrexate—testicular cancer	0.000428	0.00153	CcSEcCtD
Amphetamine—Chest pain—Doxorubicin—testicular cancer	0.000428	0.00152	CcSEcCtD
Amphetamine—Anxiety—Doxorubicin—testicular cancer	0.000426	0.00152	CcSEcCtD
Amphetamine—Anorexia—Epirubicin—testicular cancer	0.000422	0.00151	CcSEcCtD
Amphetamine—Dyspnoea—Methotrexate—testicular cancer	0.000422	0.0015	CcSEcCtD
Amphetamine—Somnolence—Methotrexate—testicular cancer	0.000421	0.0015	CcSEcCtD
Amphetamine—Dry mouth—Doxorubicin—testicular cancer	0.000418	0.00149	CcSEcCtD
Amphetamine—Dyspepsia—Methotrexate—testicular cancer	0.000417	0.00149	CcSEcCtD
Amphetamine—SLC6A4—NRF2 pathway—SLC2A6—testicular cancer	0.000415	0.043	CbGpPWpGaD
Amphetamine—Decreased appetite—Methotrexate—testicular cancer	0.000412	0.00147	CcSEcCtD
Amphetamine—Anaphylactic shock—Doxorubicin—testicular cancer	0.00041	0.00146	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000409	0.00146	CcSEcCtD
Amphetamine—Fatigue—Methotrexate—testicular cancer	0.000408	0.00145	CcSEcCtD
Amphetamine—Infection—Doxorubicin—testicular cancer	0.000407	0.00145	CcSEcCtD
Amphetamine—Insomnia—Epirubicin—testicular cancer	0.000401	0.00143	CcSEcCtD
Amphetamine—Tachycardia—Doxorubicin—testicular cancer	0.0004	0.00143	CcSEcCtD
Amphetamine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000396	0.00141	CcSEcCtD
Amphetamine—Dyspnoea—Epirubicin—testicular cancer	0.000395	0.00141	CcSEcCtD
Amphetamine—Somnolence—Epirubicin—testicular cancer	0.000394	0.0014	CcSEcCtD
Amphetamine—Anorexia—Doxorubicin—testicular cancer	0.000391	0.00139	CcSEcCtD
Amphetamine—Dyspepsia—Epirubicin—testicular cancer	0.00039	0.00139	CcSEcCtD
Amphetamine—Gastrointestinal pain—Methotrexate—testicular cancer	0.000387	0.00138	CcSEcCtD
Amphetamine—Decreased appetite—Epirubicin—testicular cancer	0.000385	0.00137	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000383	0.00136	CcSEcCtD
Amphetamine—Fatigue—Epirubicin—testicular cancer	0.000382	0.00136	CcSEcCtD
Amphetamine—Constipation—Epirubicin—testicular cancer	0.000379	0.00135	CcSEcCtD
Amphetamine—Urticaria—Methotrexate—testicular cancer	0.000376	0.00134	CcSEcCtD
Amphetamine—Abdominal pain—Methotrexate—testicular cancer	0.000374	0.00133	CcSEcCtD
Amphetamine—Body temperature increased—Methotrexate—testicular cancer	0.000374	0.00133	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—INSL3—testicular cancer	0.000373	0.0386	CbGpPWpGaD
Amphetamine—Insomnia—Doxorubicin—testicular cancer	0.000371	0.00132	CcSEcCtD
Amphetamine—Dyspnoea—Doxorubicin—testicular cancer	0.000366	0.0013	CcSEcCtD
Amphetamine—Somnolence—Doxorubicin—testicular cancer	0.000364	0.0013	CcSEcCtD
Amphetamine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000362	0.00129	CcSEcCtD
Amphetamine—Dyspepsia—Doxorubicin—testicular cancer	0.000361	0.00129	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—SLC2A6—testicular cancer	0.000357	0.0369	CbGpPWpGaD
Amphetamine—Decreased appetite—Doxorubicin—testicular cancer	0.000356	0.00127	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000354	0.00126	CcSEcCtD
Amphetamine—Fatigue—Doxorubicin—testicular cancer	0.000353	0.00126	CcSEcCtD
Amphetamine—Urticaria—Epirubicin—testicular cancer	0.000352	0.00125	CcSEcCtD
Amphetamine—Constipation—Doxorubicin—testicular cancer	0.000351	0.00125	CcSEcCtD
Amphetamine—Body temperature increased—Epirubicin—testicular cancer	0.00035	0.00125	CcSEcCtD
Amphetamine—Abdominal pain—Epirubicin—testicular cancer	0.00035	0.00125	CcSEcCtD
Amphetamine—Hypersensitivity—Methotrexate—testicular cancer	0.000349	0.00124	CcSEcCtD
Amphetamine—Asthenia—Methotrexate—testicular cancer	0.00034	0.00121	CcSEcCtD
Amphetamine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000335	0.00119	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000334	0.0346	CbGpPWpGaD
Amphetamine—Hypersensitivity—Epirubicin—testicular cancer	0.000326	0.00116	CcSEcCtD
Amphetamine—Urticaria—Doxorubicin—testicular cancer	0.000326	0.00116	CcSEcCtD
Amphetamine—Abdominal pain—Doxorubicin—testicular cancer	0.000324	0.00115	CcSEcCtD
Amphetamine—Body temperature increased—Doxorubicin—testicular cancer	0.000324	0.00115	CcSEcCtD
Amphetamine—Diarrhoea—Methotrexate—testicular cancer	0.000324	0.00115	CcSEcCtD
Amphetamine—Asthenia—Epirubicin—testicular cancer	0.000318	0.00113	CcSEcCtD
Amphetamine—SLC6A3—NRF2 pathway—SLC2A6—testicular cancer	0.000316	0.0327	CbGpPWpGaD
Amphetamine—Dizziness—Methotrexate—testicular cancer	0.000313	0.00112	CcSEcCtD
Amphetamine—Diarrhoea—Epirubicin—testicular cancer	0.000303	0.00108	CcSEcCtD
Amphetamine—Hypersensitivity—Doxorubicin—testicular cancer	0.000302	0.00108	CcSEcCtD
Amphetamine—Vomiting—Methotrexate—testicular cancer	0.000301	0.00107	CcSEcCtD
Amphetamine—Rash—Methotrexate—testicular cancer	0.000299	0.00106	CcSEcCtD
Amphetamine—Dermatitis—Methotrexate—testicular cancer	0.000298	0.00106	CcSEcCtD
Amphetamine—Headache—Methotrexate—testicular cancer	0.000297	0.00106	CcSEcCtD
Amphetamine—Asthenia—Doxorubicin—testicular cancer	0.000294	0.00105	CcSEcCtD
Amphetamine—Dizziness—Epirubicin—testicular cancer	0.000293	0.00104	CcSEcCtD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000289	0.0299	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000288	0.0298	CbGpPWpGaD
Amphetamine—Vomiting—Epirubicin—testicular cancer	0.000282	0.001	CcSEcCtD
Amphetamine—Nausea—Methotrexate—testicular cancer	0.000281	0.001	CcSEcCtD
Amphetamine—Diarrhoea—Doxorubicin—testicular cancer	0.000281	0.001	CcSEcCtD
Amphetamine—Rash—Epirubicin—testicular cancer	0.000279	0.000996	CcSEcCtD
Amphetamine—Dermatitis—Epirubicin—testicular cancer	0.000279	0.000995	CcSEcCtD
Amphetamine—Headache—Epirubicin—testicular cancer	0.000278	0.000989	CcSEcCtD
Amphetamine—Dizziness—Doxorubicin—testicular cancer	0.000271	0.000966	CcSEcCtD
Amphetamine—CYP2A6—NRF2 pathway—SLC2A6—testicular cancer	0.000264	0.0273	CbGpPWpGaD
Amphetamine—Nausea—Epirubicin—testicular cancer	0.000263	0.000938	CcSEcCtD
Amphetamine—Vomiting—Doxorubicin—testicular cancer	0.000261	0.000929	CcSEcCtD
Amphetamine—Rash—Doxorubicin—testicular cancer	0.000259	0.000921	CcSEcCtD
Amphetamine—Dermatitis—Doxorubicin—testicular cancer	0.000258	0.00092	CcSEcCtD
Amphetamine—Headache—Doxorubicin—testicular cancer	0.000257	0.000915	CcSEcCtD
Amphetamine—Nausea—Doxorubicin—testicular cancer	0.000244	0.000868	CcSEcCtD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000225	0.0233	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—INSL3—testicular cancer	0.000211	0.0218	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000199	0.0206	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—INSL3—testicular cancer	0.000191	0.0198	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—HPGDS—testicular cancer	0.000173	0.0179	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00017	0.0176	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000147	0.0152	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000146	0.0152	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000114	0.0118	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000114	0.0118	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—INSL3—testicular cancer	0.000113	0.0117	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000101	0.0105	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—INSL3—testicular cancer	8.7e-05	0.00901	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—HPGDS—testicular cancer	8.41e-05	0.0087	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—INSL3—testicular cancer	4.92e-05	0.00509	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—HPGDS—testicular cancer	4.71e-05	0.00488	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—INSL3—testicular cancer	4.47e-05	0.00462	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—H2AFZ—testicular cancer	3.62e-05	0.00375	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STK11—testicular cancer	3.6e-05	0.00373	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KITLG—testicular cancer	3.33e-05	0.00345	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—HPGDS—testicular cancer	2.95e-05	0.00306	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—INSL3—testicular cancer	2.64e-05	0.00273	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—HPGDS—testicular cancer	2.5e-05	0.00258	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—FGFR3—testicular cancer	2.48e-05	0.00256	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KIT—testicular cancer	2.27e-05	0.00235	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—STK11—testicular cancer	2.14e-05	0.00222	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—STK11—testicular cancer	1.81e-05	0.00188	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HPGDS—testicular cancer	1.44e-05	0.00149	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—STK11—testicular cancer	1.04e-05	0.00108	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—H2AFZ—testicular cancer	8.44e-06	0.000874	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STK11—testicular cancer	8.4e-06	0.000869	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HPGDS—testicular cancer	8.06e-06	0.000835	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KITLG—testicular cancer	7.77e-06	0.000804	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—STK11—testicular cancer	5.86e-06	0.000606	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGFR3—testicular cancer	5.77e-06	0.000598	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KIT—testicular cancer	5.3e-06	0.000549	CbGpPWpGaD
